Researchers have developed new small antibodies, nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. In a new study, published in Science, researchers from Karolinska Institutet in collaboration with
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
The COVID-19 pandemic
AdaptVac has announced the publication of strong virus neutralization animal proof-of-concept data for its capsid virus like particle (cVLP) based SARS-CoV-2 subunit vaccine in Nature Communications. The vaccine elicited antibodies
Swedish medtech start-up Capitainer has closed a share issue of SEK 31 million to roll out its new qDBS dried blood spot testing system. Led by Sciety the target was
Pfizer and BioNTech have announced results from an in vitro study that shows the antibodies from people who have received their vaccine effectively neutralize SARS-CoV-2 with a key mutation that
AstraZeneca’s COVID-19 vaccine has been granted emergency use authorization in India as well as Argentina, Dominican Republic, El Salvador, Mexico and Morocco for the active immunization of adults. The approval
The European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union. The
Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of
NLS News
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly
Immunicum has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue
An international collaboration project to develop and implement novel genome-based disease prediction tools has received over 10 million euros from the EU Horizon 2020 Research and Innovation program. The project
Biogen has announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline
In May 2021 the Medical Device Directive (MDD) and the Active Implantable Medical Devices (AIMD) will be replaced by the Medical Device Regulation (MDR) in the EU. What does this
AstraZeneca and Daiichi Sankyo have been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Exact Therapeutics has announced a collaboration with GE Healthcare to develop an ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT) across multiple disease conditions. “We
The Swedish-Danish type 1 diabetes project DiaUnion has received an additional EUR 1 million funding to investigate the link between type 1 diabetes and related autoimmune diseases. Type 1 diabetes
Recipharm and Enzymatica have signed a broadened contract for the manufacture of ColdZyme. The agreement will involve an additional Recipharm production site in Pianezza, Italy, to support Enzymatica in increasing
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who
Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase augmentation of its plasmid DNA services as a continuation of its Gene Therapy services’ expansion
OssDsign has completed the acquisition of Sirakoss. The transaction was announced on November 3, 2020. USD 11 million OssDsign has acquired all outstanding Sirakoss shares in an all-cash transaction. The
Drug and device development
Novo Nordisk has announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly
Gesynta Pharma has announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis. Systemic sclerosis is
Nanoform has announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful, states the company in its press release. Phase
Lytix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various
Profile
What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company. Fascinated by the
In a new job
The method of storytelling has been an excellent way to spread information, knowledge and experiences for centuries. For ages mankind has gathered around the camp fire to tell each other
The Center for Translational Research Sweden (CTR) has announced that the Board has appointed Karin Meyer as their new Chief Executive Officer. Karin Meyer succeeds Mats Lindquist who has been
Elekta has announced that Gustaf Salford has been appointed to the role of President and CEO, effective immediately. Salford has been Acting CEO since early June 2020. Elekta’s Board of
Careers
As Swedish clinicians treating large numbers of asthma patients, Henrik Ljungberg and Björn Nordlund often spent time reviewing the multiple prescriptions and directives patients received from different providers after flare-ups.
Read the latest issue of our magazine!
No 04 2020 // This issue includes an exclusive interview with Evelina Vågesjö, co-founder and CEO of Ilya Pharma, who turned her thesis project into a successful company. Nordic venture capitalists share their perspectives and advice when it comes to raising capital and we take a closer look at the life science industry in Philadelphia, US, where cell and gene therapy is fast becoming a local specialty.
You may also learn more about having a career within clinical research and what to consider when the Medical Device Directive is replaced by the Medical Device Regulation. Scientists in Finland have found a new piece in the Parkinson’s puzzle and SwedenBIO shares their thoughts on how we can secure the right expertise in the future.
The Nobel Prize 2019
Sir Peter J. Ratcliffe defined a system involved in inflammation, metabolism, cancer, and more. On 7 October 2019, Sir Peter J. Ratcliffe was having a typical scientist’s day, writing a
Since nothing is more basic to life than oxygen, Dr. Gregg Semenza, MD, PhD, found it logical to want to unravel some of the complexities of how cells monitor and
William Kaelin feels he has been fortunate in his scientific career. His contributions have had a great impact, not least within cancer treatment, and for future generations he emphasizes the
“It’s so satisfying that we described oxygen sensing that has been around since animal evolution. That’s a discovery for all time, so we’re just rejoicing in that.” – Sir Peter Ratcliffe
Upcoming events
The fifteenth annual BIO-Europe Spring partnering conference will be held March 22-25 in a fully digital format. The event will include on-demand early access to the company pitches, program sessions,
NLSDays is the largest Nordic partnering conference dedicated to the life science industry. The 2020 event has been postponed until the 2021 event, April 20-23 2021, delivered digitally. Since its
This event is arranged 2 days in-person and 3 days virtually. This year’s hybrid event enables you to identify, meet and network with leaders across the life science value chain.
Anglonordic is the only life science conference in the UK exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. This one
The latest research news from the Nordic region
Science Article
When Françoise Barré-Sinoussi came to Stockholm to receive the Nobel Prize in Physiology or Medicine in 2008, she felt like she was in another world. As a true scientist, her
An international collaboration project to develop and implement novel genome-based disease prediction tools has received over 10 million euros from the EU Horizon 2020 Research and Innovation program. The project
In a new study, researchers at Karolinska Institutet have used a urine test to identify and verify a patient’s type of asthma. The study, which has been published in the
The Swedish-Danish type 1 diabetes project DiaUnion has received an additional EUR 1 million funding to investigate the link between type 1 diabetes and related autoimmune diseases. Type 1 diabetes
Biomedicum in Stockholm, designed by C.F. Møller Architects for Akademiska Hus and Karolinska Institutet, is a European Union Prize for Contemporary Architecture – Mies van der Rohe Award 2022 nominee.
Researchers at Karolinska Institutet in Sweden report in the journal Nature that they have developed novel first-in-class inhibitors that compromise mitochondrial function in cancer cells. Treatment with the inhibitors stopped cancer cells
Nordic Life Science
The latest clinical trials
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly
Gesynta Pharma has announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis. Systemic sclerosis is
Nanoform has announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful, states the company in its press release. Phase
Lytix Biopharma has announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for LTX-315, an oncolytic molecule in development for various
Ultimovacs will participate in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups
Ilya Pharma has announced positive results from an extensive Phase I trial of its lead candidate ILP100 for the treatment of difficult and chronic wounds. ILP100 is the first drug
Researchers have developed new small antibodies, nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. In a new study, published in Science, researchers from Karolinska Institutet in collaboration with
Nanoform has announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever
Oncopeptides has announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone
Sign up to our newsletter